BPC 157 What Athletes Need to Know About Legality, Safety and Efficacy Training & Conditioning FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved New: An FDA decision to place 19 peptides on the unsafe list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then,